| Dry Eye Syndromes
Eysuvis vs Tyrvaya
Side-by-side clinical, coverage, and cost comparison for dry eye syndromes.Deep comparison between: Eysuvis vs Tyrvaya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTyrvaya has a higher rate of injection site reactions vs Eysuvis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tyrvaya but not Eysuvis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eysuvis
Tyrvaya
At A Glance
Ophthalmic
Four times daily
Corticosteroid
Nasal spray
Twice daily
Nicotinic acetylcholine receptor agonist
Indications
- Dry Eye Syndromes
- Dry Eye Syndromes
Dosing
Dry Eye Syndromes Instill one to two drops into each eye four times daily for up to two weeks.
Dry Eye Syndromes One spray in each nostril twice daily, approximately 12 hours apart; prime with 7 actuations before initial use and re-prime with 1 actuation if not used for more than 5 days.
Contraindications
- Most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella
- Mycobacterial infection of the eye
- Fungal diseases of ocular structures
—
Adverse Reactions
Most common (>=5%) Instillation site pain
Serious Elevated intraocular pressure, optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, delayed wound healing, secondary ocular infection from pathogens including herpes simplex, perforation of the globe
Most common (>=5%) sneezing (82%), cough (16%), throat irritation (13%), instillation-site (nose) irritation (8%)
Pharmacology
Corticosteroid that inhibits the inflammatory response by suppressing edema, fibrin deposition, capillary dilation, leukocyte migration, fibroblast proliferation, and collagen deposition, likely via inhibition of prostaglandin production through glucocorticoid receptor binding.
Nicotinic acetylcholine receptor agonist; varenicline binds heteromeric nACh receptor subtypes (alpha4beta2, alpha4alpha6beta2, alpha3beta4, alpha3alpha5beta4) and the alpha7 receptor, activating the trigeminal parasympathetic pathway to increase basal tear film production in dry eye disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eysuvis
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (10/12)
Tyrvaya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Eysuvis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Tyrvaya
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (6/8)
Humana
Eysuvis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (2/3)
Tyrvaya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Eysuvis.
No savings programs available for Tyrvaya.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EysuvisView full Eysuvis profile
TyrvayaView full Tyrvaya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.